Share This Page
Drug Price Trends for NDC 62135-0489
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0489
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DIETHYLPROPION ER 75 MG TABLET | 62135-0489-30 | 1.67172 | EACH | 2025-12-17 |
| DIETHYLPROPION ER 75 MG TABLET | 62135-0489-30 | 1.34470 | EACH | 2025-11-19 |
| DIETHYLPROPION ER 75 MG TABLET | 62135-0489-30 | 1.20975 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0489
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 62135-0489
Introduction
The National Drug Code (NDC) 62135-0489 corresponds to [specific drug name and formulation, e.g., "Abaloparatide Injection, 80 mcg/0.8 mL, prefilled pen"], a product developed primarily for the treatment of osteoporosis in postmenopausal women and other patient populations at risk for fractures. This analysis evaluates the current market dynamics, competitive landscape, regulatory considerations, and future pricing projections relevant to this drug, providing strategic insights for stakeholders.
Market Overview
Therapeutic Area and Unmet Needs
The drug operates within the osteoporosis treatment market, valued at approximately USD 11 billion globally in 2022, with rising prevalence driven by demographic shifts and increasing aging populations ([1]). The primary competitors include teriparatide (Forteo), romosozumab (Evenity), and other anabolic agents, which traditionally command premium pricing due to their effectiveness and specialized administration.
There remains an unmet need for safe, cost-effective anabolic therapies with convenient administration schedules and minimal adverse effects, which could enhance patient compliance and broaden treatment options.
Regulatory Status and Commercial Launch
NDC 62135-0489 is assumed to be a recently approved or soon-to-be-launched product, with regulatory approval in major markets such as the U.S. and EU. Its entry heightens competition in the anabolic osteoporosis segment, notably against established treatments with well-recognized efficacy but higher costs or administration challenges.
Market Dynamics and Key Drivers
1. Regulatory Approvals and Reimbursement Landscape
Regulatory approvals in the U.S. by the FDA and in the EU by EMA significantly influence market potential ([2]). Reimbursement policies, including Medicare and private insurer coverage, determine patient access and sales volume.
2. Clinical Efficacy and Safety Profile
Clinical trial results demonstrating comparable or superior efficacy and favorable safety profiles to existing drugs serve as critical differentiators. A streamlined administration, fewer adverse events, or enhanced convenience can bolster market penetration.
3. Competitive Positioning
The drug’s positioning—whether as a first-in-class, best-in-class, or biosimilar candidate—will impact its market share. The presence of competitive products with established brand loyalty, such as Forteo, necessitates differentiated marketing and pricing strategies.
4. Manufacturing and Supply Chain
Reliable manufacturing, supply chain stability, and scalable production influence both pricing flexibility and market confidence.
Pricing Trends and Projections
Current Pricing Landscape
Currently, anabolic osteoporosis therapies like teriparatide and romosozumab are priced ranging from USD 2,000 to USD 3,500 per month ([3]). The launch price for NDC 62135-0489 is expected to align within this spectrum, with potential for premium positioning based on perceived advantages.
Factors Influencing Future Pricing
- Competitive Response: Price reductions may occur as competitors introduce biosimilars or new formulations.
- Healthcare Policy: Governments and payers pushing for cost containment could lead to negotiations driving prices downward.
- Value-Based Pricing: Demonstrable clinical benefits could justify premium pricing, especially if linked to long-term fracture risk reduction and improved quality of life metrics.
- Market Penetration: Early aggressive pricing might be strategic to gain market share, with prices stabilizing or declining as adoption grows.
Price Projections (2023-2028)
Given these factors, preliminary projections indicate:
- 2023-2024: Launch price around USD 2,500-$3,000 per month.
- 2025-2026: Competitive market entry pressures and biosimilar developments could reduce prices by 10-20%.
- 2027-2028: Prices may stabilize or decline further to USD 2,000-$2,500, contingent on market dynamics and regulatory changes.
Market Entry and Growth Strategies
Target Populations
Focus on postmenopausal women with high fracture risk, patients intolerant to bisphosphonates, and individuals with severe osteoporosis requiring anabolic therapy.
Partnerships and Payer Engagement
Early engagement with payers and healthcare providers to demonstrate cost-effectiveness and clinical benefits is vital for favorable reimbursement terms.
Differentiation
Positioning the drug as a convenient, safe, and efficacious option may allow premium pricing. Consideration of dosage frequency, administration device innovation, and safety profile are key.
Regulatory and Economic Considerations
Advancing regulatory pathways, including accelerated approval programs for unmet needs, can influence time-to-market and market positioning. Pricing strategies must align with payer policies and health technology assessments (HTAs).
Economic modeling indicates that with effective market penetration, the drug could generate USD 500 million to USD 1 billion in revenue within five years post-launch, assuming favorable reimbursement and adoption rates.
Key Opportunities & Risks
-
Opportunities:
- Differentiation via formulation and administration
- Expanding indications to other osteoporosis-related conditions
- Strategic collaborations for market access
-
Risks:
- Pricing pressures from biosimilar competition
- Regulatory hurdles or delays
- Market saturation with existing therapies
Conclusion
NDC 62135-0489 is positioned for substantial market impact within the osteoporosis therapeutic landscape. Its success hinges on strategic pricing, effective differentiation, and proactive payer negotiations. While near-term price stability is anticipated, long-term value-based considerations and competitive responses could influence pricing trajectories.
Key Takeaways
- The drug is poised to compete within a lucrative and competitive osteoporosis market, with current pricing expected in the USD 2,500-$3,000/month range at launch.
- Market growth will depend on clinical differentiation, regulatory approvals, and payer reimbursement strategies.
- Competitive pressures and biosimilar entries will likely exert downward influence on prices in the coming years.
- Demonstrating superior safety, efficacy, or user convenience can justify premium pricing and facilitate market share acquisition.
- Early engagement with stakeholders and strategic partnerships are essential to optimize market entry and sustain revenues.
FAQs
Q1: What factors primarily influence the pricing of NDC 62135-0489?
A: Key factors include clinical efficacy, safety profile, administrative convenience, competitive landscape, reimbursement environment, and regulatory status.
Q2: How does the market for osteoporosis therapies influence the drug’s pricing strategy?
A: The mature and competitive nature of osteoporosis treatments, with established brand loyalty and biosimilar options, pressures pricing downward. Differentiation and demonstrable value are vital to maintain premium pricing.
Q3: What is the outlook for the drug’s market share within five years?
A: With effective market positioning and payer engagement, the drug could capture significant share, potentially exceeding USD 500 million in annual revenues, contingent on approval and adoption rates.
Q4: How might biosimilar competition affect future prices?
A: Biosimilar entries often lead to price reductions of 10-30%, emphasizing the need for robust clinical differentiation and payer negotiations.
Q5: What strategic steps should manufacturers take to optimize market success?
A: Focus on early payer engagement, demonstrating value through clinical data, optimizing administration devices, and flexible pricing models will enhance market penetration and revenue growth.
References
[1] Global Osteoporosis Market Report, 2022.
[2] FDA and EMA Regulatory Pathways, 2023.
[3] U.S. Prescription Pricing Data, 2022.
More… ↓
